Beyond the Abstract - Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
BERKELEY, CA (UroToday.com) - Non-adherence or discontinuation is widespread in patients treated with antimuscarinic therapy for overactive bladder (OAB), but switching to another antimuscarinic agent could improve symptoms in patients who have had an unsatisfactory experience with prior treatment.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
